GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (WBO:CVAC) » Definitions » Accumulated other comprehensive income (loss)

CureVac NV (WBO:CVAC) Accumulated other comprehensive income (loss) : €2,068.8 Mil (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is CureVac NV Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. CureVac NV's Accumulated other comprehensive income (loss) for the quarter that ended in Sep. 2024 was €2,068.8 Mil.

CureVac NV's quarterly Accumulated other comprehensive income (loss) increased from Mar. 2024 (€2,056.5 Mil) to Jun. 2024 (€2,058.7 Mil) and increased from Jun. 2024 (€2,058.7 Mil) to Sep. 2024 (€2,068.8 Mil).

CureVac NV's annual Accumulated other comprehensive income (loss) increased from Dec. 2021 (€1,728.6 Mil) to Dec. 2022 (€1,817.1 Mil) and increased from Dec. 2022 (€1,817.1 Mil) to Dec. 2023 (€2,056.0 Mil).

CureVac NV Accumulated other comprehensive income (loss) Historical Data

The historical data trend for CureVac NV's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Accumulated other comprehensive income (loss) Chart

CureVac NV Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accumulated other comprehensive income (loss)
Get a 7-Day Free Trial 461.54 1,334.76 1,728.62 1,817.15 2,056.04

CureVac NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,054.72 2,056.04 2,056.53 2,058.69 2,068.81

CureVac NV Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

CureVac NV Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of CureVac NV's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

CureVac NV Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (WBO:CVAC) » Definitions » Accumulated other comprehensive income (loss)
Comparable Companies
RYZB MRUS AGIO ZNTL ABCL RXRX MNKD TGTX SAGE HRMY OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
CVAC:USA 1CVAC:Italy 0A9E:UK 5CV:Germany
Address
Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076
Website
https://www.curevac.com
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.